Previous close | 1,001.50 |
Open | 1,004.00 |
Bid | 680.00 x 0 |
Ask | 1,025.00 x 0 |
Day's range | 1,000.50 - 1,010.50 |
52-week range | 887.00 - 1,315.00 |
Volume | |
Avg. volume | 3,744,691 |
Market cap | 8.783B |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | 41.85 |
EPS (TTM) | 0.24 |
Earnings date | 01 Aug 2024 |
Forward dividend & yield | 0.30 (3.03%) |
Ex-dividend date | 28 Mar 2024 |
1y target est | 12.92 |
Key Insights Smith & Nephew's estimated fair value is UK£15.04 based on 2 Stage Free Cash Flow to Equity Current share...
Key Insights Given the large stake in the stock by institutions, Smith & Nephew's stock price might be vulnerable to...
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology company is pleased to announce exciting data for its ALLEVYN LIFE Dressing in a recent study by Professor Amit Gefen and his research group published in the International Wound Journal,1 that shows a novel mechanism of action relating to pressure injury prevention (PIP). The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissip